CN110055338A - 一种弥漫性大b细胞淋巴瘤基因突变检测试剂盒 - Google Patents
一种弥漫性大b细胞淋巴瘤基因突变检测试剂盒 Download PDFInfo
- Publication number
- CN110055338A CN110055338A CN201910288999.7A CN201910288999A CN110055338A CN 110055338 A CN110055338 A CN 110055338A CN 201910288999 A CN201910288999 A CN 201910288999A CN 110055338 A CN110055338 A CN 110055338A
- Authority
- CN
- China
- Prior art keywords
- gene
- dlbcl
- kcng1
- lymphoid tumor
- cell lymphoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 35
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 26
- 210000003719 b-lymphocyte Anatomy 0.000 title claims abstract description 23
- 208000019420 lymphoid neoplasm Diseases 0.000 title claims abstract description 20
- 101001047102 Homo sapiens Potassium voltage-gated channel subfamily G member 1 Proteins 0.000 claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 36
- 230000035772 mutation Effects 0.000 claims abstract description 24
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims abstract description 12
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims abstract description 12
- 101150053046 MYD88 gene Proteins 0.000 claims abstract description 12
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims abstract description 10
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims abstract description 10
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims abstract description 10
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims abstract description 10
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 claims abstract description 10
- 102000001756 Notch2 Receptor Human genes 0.000 claims abstract description 10
- 108010029751 Notch2 Receptor Proteins 0.000 claims abstract description 10
- 108010011005 STAT6 Transcription Factor Proteins 0.000 claims abstract description 10
- 102000013968 STAT6 Transcription Factor Human genes 0.000 claims abstract description 10
- 108020004414 DNA Proteins 0.000 claims description 34
- 238000012163 sequencing technique Methods 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 239000011324 bead Substances 0.000 claims description 13
- 238000012165 high-throughput sequencing Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 8
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 3
- 238000013467 fragmentation Methods 0.000 claims description 2
- 238000006062 fragmentation reaction Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 abstract description 13
- 238000004393 prognosis Methods 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 101150080074 TP53 gene Proteins 0.000 abstract description 2
- 230000002068 genetic effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 108700025694 p53 Genes Proteins 0.000 abstract description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 66
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000000869 mutational effect Effects 0.000 description 5
- 238000007481 next generation sequencing Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 2
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 2
- 101150001392 CD79B gene Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000001280 germinal center Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000007403 mPCR Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 102100022783 Potassium voltage-gated channel subfamily G member 1 Human genes 0.000 description 1
- 208000015695 Primary lymphedema Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 1
- 229950005309 fostamatinib Drugs 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229950004774 tazemetostat Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910288999.7A CN110055338B (zh) | 2019-04-11 | 2019-04-11 | 一种弥漫性大b细胞淋巴瘤基因突变检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910288999.7A CN110055338B (zh) | 2019-04-11 | 2019-04-11 | 一种弥漫性大b细胞淋巴瘤基因突变检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110055338A true CN110055338A (zh) | 2019-07-26 |
CN110055338B CN110055338B (zh) | 2023-09-05 |
Family
ID=67317614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910288999.7A Active CN110055338B (zh) | 2019-04-11 | 2019-04-11 | 一种弥漫性大b细胞淋巴瘤基因突变检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110055338B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111304323A (zh) * | 2019-12-31 | 2020-06-19 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 一组评估nk/t细胞淋巴瘤发病风险相关的snp标志物及其应用 |
CN111584001A (zh) * | 2020-02-13 | 2020-08-25 | 上海交通大学医学院附属瑞金医院 | 一种用于淋巴瘤预后判断的方法、试剂盒及应用 |
CN111621565A (zh) * | 2020-05-07 | 2020-09-04 | 杭州可帮基因科技有限公司 | 弥漫性大b细胞淋巴瘤分子分型试剂盒及分型装置 |
CN112226512A (zh) * | 2020-10-21 | 2021-01-15 | 东南大学 | 一种用于恶性淋巴瘤液体活检的基因组合与方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080280297A1 (en) * | 2005-07-15 | 2008-11-13 | The Trustees Of Columbia University In The City Of | Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia |
CN101506379A (zh) * | 2006-05-22 | 2009-08-12 | 临床基因组学有限公司 | 检测方法 |
US20160153053A1 (en) * | 2010-08-31 | 2016-06-02 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
US20180223368A1 (en) * | 2015-03-18 | 2018-08-09 | Memorial Sloan Ketteting Cancer Center | Methods for diagnosing and treating follicular lymphoma |
CN108823640A (zh) * | 2018-06-06 | 2018-11-16 | 珠海铂华生物工程有限公司 | 一种构建基于淋巴瘤基因检测的高通量测序文库的方法及其应用 |
-
2019
- 2019-04-11 CN CN201910288999.7A patent/CN110055338B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080280297A1 (en) * | 2005-07-15 | 2008-11-13 | The Trustees Of Columbia University In The City Of | Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia |
CN101506379A (zh) * | 2006-05-22 | 2009-08-12 | 临床基因组学有限公司 | 检测方法 |
US20170260585A1 (en) * | 2006-05-22 | 2017-09-14 | Clinical Genomics Pty. Ltd. | Detection method |
US20160153053A1 (en) * | 2010-08-31 | 2016-06-02 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
US20180223368A1 (en) * | 2015-03-18 | 2018-08-09 | Memorial Sloan Ketteting Cancer Center | Methods for diagnosing and treating follicular lymphoma |
CN108823640A (zh) * | 2018-06-06 | 2018-11-16 | 珠海铂华生物工程有限公司 | 一种构建基于淋巴瘤基因检测的高通量测序文库的方法及其应用 |
Non-Patent Citations (2)
Title |
---|
陈舒等: "基于NGS的弥漫大B细胞淋巴瘤预后相关基因突变研究进展", 《中国肿瘤临床》 * |
黄耀慧等: "二代测序在弥漫大B细胞淋巴瘤中的应用", 《临床血液学杂志》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111304323A (zh) * | 2019-12-31 | 2020-06-19 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 一组评估nk/t细胞淋巴瘤发病风险相关的snp标志物及其应用 |
CN111584001A (zh) * | 2020-02-13 | 2020-08-25 | 上海交通大学医学院附属瑞金医院 | 一种用于淋巴瘤预后判断的方法、试剂盒及应用 |
CN111584001B (zh) * | 2020-02-13 | 2022-05-20 | 上海交通大学医学院附属瑞金医院 | 一种用于淋巴瘤预后判断的方法、试剂盒及应用 |
CN111621565A (zh) * | 2020-05-07 | 2020-09-04 | 杭州可帮基因科技有限公司 | 弥漫性大b细胞淋巴瘤分子分型试剂盒及分型装置 |
CN111621565B (zh) * | 2020-05-07 | 2023-12-15 | 杭州可帮基因科技有限公司 | 弥漫性大b细胞淋巴瘤分子分型试剂盒及分型装置 |
CN112226512A (zh) * | 2020-10-21 | 2021-01-15 | 东南大学 | 一种用于恶性淋巴瘤液体活检的基因组合与方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110055338B (zh) | 2023-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110055338A (zh) | 一种弥漫性大b细胞淋巴瘤基因突变检测试剂盒 | |
US20240141432A9 (en) | Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results | |
CN105087789B (zh) | 一种检测血浆cfDNA中BCR和TCR免疫组库的方法 | |
Feezor et al. | Whole blood and leukocyte RNA isolation for gene expression analyses | |
CN106544407B (zh) | 确定受体cfDNA样本中供体来源cfDNA比例的方法 | |
Baron et al. | A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft | |
CN106834275A (zh) | ctDNA超低频突变检测文库的构建方法、试剂盒及文库检测数据的分析方法 | |
EP3143163B1 (en) | Gene mutations and copy number alterations of egfr, kras and met | |
Halbritter et al. | Epigenomics and single-cell sequencing define a developmental hierarchy in Langerhans cell histiocytosis | |
CN105695567B (zh) | 一种用于检测胎儿染色体非整倍体的试剂盒、引物和探针序列及检测方法 | |
CN105063209B (zh) | 一种外泌体miRNA的定量检测方法 | |
CN105986031B (zh) | 肿瘤易感62基因及其应用 | |
CN104271759B (zh) | 作为疾病信号的同种型谱的检测 | |
CA2904658A1 (en) | Method for identifying the quantitative cellular composition in a biological sample | |
CN107541561B (zh) | 提高母体外周血中胎儿游离dna浓度的试剂盒、装置及方法 | |
CN107058521B (zh) | 一种检测人体免疫状态的检测系统 | |
CN109658980A (zh) | 一种粪便基因标志物的筛选及应用 | |
CN107893116A (zh) | 用于检测基因突变的引物对组合、试剂盒以及构建文库的方法 | |
CN116356001B (zh) | 一种基于血液循环肿瘤dna的双重背景噪声突变去除方法 | |
CN108949979A (zh) | 一种通过血液样本判断肺结节良恶性的方法 | |
Shegekar et al. | The emerging role of liquid biopsies in revolutionising cancer diagnosis and therapy | |
CN103911439A (zh) | 系统性红斑狼疮羟甲基化状态的差异表达基因的分析方法和应用 | |
Fitch et al. | Human pediatric B-cell acute lymphoblastic leukemias can be classified as B-1 or B-2-like based on a minimal transcriptional signature | |
US20200270683A1 (en) | Methods for obtaining embryonic stem cell dna methylation signatures | |
CN109735611A (zh) | 一种用于检测骨髓衰竭综合征的基因组合、引物库、构建高通量测序文库的方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231101 Address after: Room 302-2, Building 3, No. 100, Feipeng Road, Guangdong Macao Cooperative Traditional Chinese Medicine Science and Technology Industrial Park, Hengqin New District, Zhuhai, Guangdong Province, 519000 Patentee after: ZHUHAI BOHUA BIOENGINEERING Co.,Ltd. Patentee after: Ezhou Bohua Biological Products Co.,Ltd. Address before: Room 105-39504 (centralized office area), No. 6 Baohua Road, Hengqin New District, Zhuhai City, Guangdong Province, 519031 Patentee before: ZHUHAI BOHUA BIOENGINEERING Co.,Ltd. |